<DOC>
	<DOCNO>NCT02632435</DOCNO>
	<brief_summary>In REaCT-Vascular Access Trastuzumab study ( REaCT-VA ) , investigator use novel method allow comparison establish standard care vascular access strategy use `` integrated consent model '' part pragmatic clinical trial . The investigator wish address non-pharmacologic issue regard standard care vascular access device . Peripherally inserted central catheter ( PICC line ) versus subcutaneously implant device ( PORTs ) .</brief_summary>
	<brief_title>Randomized Trial Standard Care Vascular Access Strategies ( Neo ) Adjuvant Trastuzumab-based Breast Cancer Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm primary breast cancer Planned start trastuzumab base neo/adjuvant therapy : FECDH ACDH , ; dosedense ACTH , docetaxel/cyclophosphamide/trastuzumab docetaxel/carboplatin/trastuzumab , weekly paclitaxel trastuzumab . ≥19 year age Able provide verbal consent Exclusion Criteria • Contraindication central line placement .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HER2 positive</keyword>
</DOC>